Skip to main content
SpringerLink
Log in

Quality of Life and Treatment Satisfaction After the Addition of Lamivudine or Lamivudine plus Loviride to Zidovudine-Containing Regimens in Treatment-Experienced Patients with HIV Infection

  • Original Research Article
  • Quality of Life
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

Abstract

Background: Assessments of health-related quality of life and treatment satisfaction were conducted as part of a randomised, double-blind, placebo-controlled 52-week trial conducted in Canada, Australia, Europe, and South Africa (CAESAR). The Medical Outcomes Study HIV Health Survey (MOS-HIV) was selfadministered during 3 scheduled clinic visits (baseline, week 28 and the end-of-treatment/withdrawal visit). A single question was used at the end of treatment to assess patient satisfaction with study medications.

Methods: Patients were randomly allocated to receive placebo, lamivudine (150mg twice daily) or lamivudine (150mg twice daily) plus loviride (100mg 3 times daily) in addition to their current treatment regimen, which could be either zidovudine monotherapy, or zidovudine in combination with didanosine or zalcitabine at standard dosages.

Results: Statistically significant differences across treatment groups were demonstrated for the Physical and Mental Health Summary scores, and for 5 of 10 MOS-HIV subscales (physical functioning, vitality, cognitive functioning, general health perceptions, social functioning). These differences favoured the lamivudine and lamivudine plus loviride groups over the placebo group (p < 0.05). No significant difference was found between the 3 treatment groups with regard to the percentages of patients who were satisfied with their study medication.

Conclusion: The results suggest that, for treatment-experienced patients with HIV infection and CD4+ counts <250 cells/mm3, the addition of lamivudine or lamivudine plus loviride to antiretroviral regimens containing zidovudine maintained patient-reported mental and physical health.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997; 337: 725–33

    Article  PubMed  CAS  Google Scholar 

  2. Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997; 337: 734–9

    Article  PubMed  CAS  Google Scholar 

  3. Wu AW, Revicki DA, Jacobson D, et al. Evidence for reliability, validity and usefulness of the medical outcomes study HIV health survey (MOS-HIV). Q Life Res 1997; 6: 481–93

    Article  CAS  Google Scholar 

  4. Wu AW, Mathews WC, Brysk LT, et al. Quality of life in a placebo-controlled trial of zidovudine in patients with AIDS and AIDS-related complex in AIDS clinical trials. J Acquir Immune Defic Syndr Hum Retrovirol 1990; 3: 638–90

    Google Scholar 

  5. Wu AW, Hays RD, Kelly S, et al. Applications of the medical outcomes study health-related quality of life measures in HIV/AIDS. Q Life Res 1997; 6: 531–54

    Article  CAS  Google Scholar 

  6. Bozzette SA, Kanouse DE, Berry S, et al. Health status and function with zidovudine or zalcitabine as initial therapy for AIDS: a randomized controlled trial (ACTG 114). JAMA 1995; 273: 295–301

    Article  PubMed  CAS  Google Scholar 

  7. Revicki DA, Swartz C. Quality of life outcomes of saquinavir, zalcitabine, and combination saquinavir-zalcitabine therapy for advanced HIV-infection [abstract]. 4th International Conference on Retroviral and Opportunistic Infections; 1997 Jan 22-26; Washington DC, 266

  8. Nabulsi A, Revicki D, Conway D, et al. Quality of life consequences of adding ritonavir to current anti-viral therapy for advanced HIV patients. XI International Conference on AIDS; 1996 Jul 7-12; Vancouver

  9. Wu AW, Rubin HR, Mathews WC, et al. Functional status and well-being in a placebo-controlled trial of zidovudine in early AIDS-related complex. J AIDS 1993; 6: 452–8

    CAS  Google Scholar 

  10. De Boer JB, van Dam FSAM, Sprangers MAG, et al. Longitudinal study on the quality of life of symptomatic HIV-infected patients in a trial of zidovudine and interferon-alpha. AIDS 1993; 7: 947–53

    Article  PubMed  Google Scholar 

  11. Scott-Lennox JA, Adams JE, Lee JT, et al. Quality of life associated with zidovudine plus lamivudine combination treatment in therapy-naive HIV-infected patients. 3rd International Conference on Retroviral and Opportunistic Infections 1996; Jan 28-Feb 1, 1996: P119

  12. Scott-Lennox JA, Mills RJ, Burt ME. Impact of zidovudine plus lamivudine or zalcitabine on health-related quality of life. Ann Pharmacother 1998 May; 32 (5): 525–30

    Article  PubMed  CAS  Google Scholar 

  13. Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial. Lancet 1997; 349: 1413–21

  14. Wu AW, Johns Hopkins University. MOS-HIV health survey — scoring guidelines. Med Outcomes Trust 1996; 297: 1–15

    Google Scholar 

  15. Revicki DA, Sorensen S, Wu AW. Reliability and validity of the physical and mental health summary scores from the Medical Outcomes Study HIV Health Survey. Med Care 1998; 36 (2): 126–37

    Article  PubMed  CAS  Google Scholar 

  16. van Elteren PH. On the combination of independent two-sample tests of Wilcoxon. Bull Int Stat Inst 1958; 37 (Pt 3): 351–61

    Google Scholar 

  17. Wu AW, Jacobson D, Clark B, et al. Quality of life associated with valacyclovir vs high and low dose acyclovir for prophylaxis against cytomegalovirus in AIDS [abstract]. 4th International Conference on Retroviral and Opportunistic Infections; 1997 Jan 22-26; Washington DC, 297

  18. Department of Health and Human Services and Henry J. Kaiser Family Foundation. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. MMWR Morb Mortal Wkly Rep 1998; 47 (RR-5): 43–82

    Google Scholar 

  19. USPHS/IDSA Prevention of Opportunistic Infections Working Group. 1997 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. MMWR Morb Mortal Wkly Rep 1997; 46 (RR-12): 1–46

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Office of Health Policy and Clinical Outcomes, Thomas Jefferson University, Philadelphia, Pennsylvania, 19107-5099, USA

    M.L. Chatterton

  2. Outcomes Research Associates, Hillsborough, North Carolina, USA

    J. Scott-Lennox

  3. School of Hygiene and Public Health, Johns Hopkins University, Baltimore, Maryland, USA

    A.W. Wu

  4. Glaxo Wellcome Inc Research Triangle Park, North Carolina, USA

    J. Scott

Authors
  1. M.L. Chatterton
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. Scott-Lennox
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A.W. Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J. Scott
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M.L. Chatterton.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chatterton, M., Scott-Lennox, J., Wu, A. et al. Quality of Life and Treatment Satisfaction After the Addition of Lamivudine or Lamivudine plus Loviride to Zidovudine-Containing Regimens in Treatment-Experienced Patients with HIV Infection. Pharmacoeconomics 15 (Suppl 1), 67–74 (1999). https://doi.org/10.2165/00019053-199915001-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-199915001-00006

Keywords

Search

Navigation